KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $8.71 to $9.09
• 50-Day Range: $7.40 to $10.27
• 52-Week Range: $7.30 to $16.88
• Volume: 381,957 shs
• Average Volume: 283,182 shs
• Market Capitalization: $433.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

KalVista Pharmaceuticals Stock Analysis - MarketRank™

KalVista Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 144th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

KalVista Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of KalVista Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KalVista Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KalVista Pharmaceuticals has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.36% of the outstanding shares of KalVista Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.

Change versus previous month

Short interest in KalVista Pharmaceuticals has recently increased by 1.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KalVista Pharmaceuticals does not currently pay a dividend.

Dividend Growth

KalVista Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.17

Percentage of Shares Shorted

15.36% of the outstanding shares of KalVista Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.

Change versus previous month

Short interest in KalVista Pharmaceuticals has recently increased by 1.88%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.51

News Sentiment

KalVista Pharmaceuticals has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for KalVista Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for KALV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $304,086.00 in company stock.

Percentage Held by Insiders

10.50% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

KALV Stock Analysis - Frequently Asked Questions

How have KALV shares performed this year?

KalVista Pharmaceuticals' stock was trading at $8.47 on January 1st, 2025. Since then, KALV shares have increased by 3.5% and is now trading at $8.77.
View the best growth stocks for 2025 here.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings data on Thursday, December, 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01.

Who are KalVista Pharmaceuticals' major shareholders?

KalVista Pharmaceuticals' top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.15%), SG Americas Securities LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Venrock Healthcare Capital Par, Benjamin L Palleiko, Thomas Andrew Crockett, Paul K Audhya, Christopher Yea, Edward P Feener and Albert Cha.
View institutional ownership trends.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX).

Company Calendar

• Last Earnings: 12/05/2024
• Today: 1/30/2025
• Next Earnings (Estimated): 3/10/2025
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KALV
• CUSIP: N/A
• CIK: 1348911
• Web: www.kalvista.com
• Phone: 857-999-0075
• Fax: 866-553-3269
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +179.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -103.92%
• Return on Assets: -88.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.87
• Quick Ratio: 6.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 1.84

Miscellaneous

• Outstanding Shares: 49,420,000
• Free Float: 44,229,000
• Market Cap: $442.31 million
• Optionable: Optionable
• Beta: 0.86